Skip to content

Sinovac

Recent events

Recent events tied to this brand in public sources.

Back to profile6 entries

  1. 2022

    Sinovac and the CAS Institute of Biophysics sign a strategic cooperation agreement

    Sinovac Holdings and the Institute of Biophysics of the Chinese Academy of Sciences signed a strategic cooperation agreement to collaborate in life-health fields including vaccine and drug research and development. Sinovac Holdings will invest RMB 50 million during the agreement period to support a joint laboratory, joint research commercialization, and a research award.

  2. 2021

    Locally filled Sinovac vaccine begins supply to Myanmar

    Pharmaniaga said its locally filled Sinovac COVID-19 vaccine received an order from a Myanmar company and began shipments to supply the Myanmar market on November 13, marking the vaccine's first entry into an international market.

  3. 2021

    Philippine FDA approves Sinovac vaccine clinical trial application

    The Philippine Food and Drug Administration approved Sinovac Biotech’s application to conduct clinical trials of its COVID-19 vaccine in the Philippines.

  4. 2020

    Sinovac announces plan to expand CoronaVac production capacity

    Sinovac said it could manufacture 300 million vaccine doses annually and aimed to complete construction of a second production facility by the end of 2020, increasing annual Covid-19 vaccine production capacity to 600 million doses.

  5. 2020

    Sinovac secures $515 million investment to support CoronaVac development and production

    Sino Biopharmaceutical said a business unit would invest $515 million in Sinovac Life Sciences to help develop and produce CoronaVac. The investment would give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences.

  6. 2020

    Sinovac secures approximately $500 million in funding for COVID-19 vaccine development

    Sinovac Biotech said it had secured approximately $500 million in funding for COVID-19 vaccine development. The company identified Sino Biopharmaceutical Ltd. as the investor.